Cyclin-dependent kinase 5 activates guanine nucleotide exchange factor GIV/Girdin to orchestrate

Deepali Bhandari1, Inmaculada Lopez-Sanchez2, Andrew To3

  • 1Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093-0651; Department of Chemistry and Biochemistry, California State University Long Beach, Long Beach, CA 90840-9507; prghosh@ucsd.edu deepali.bhandari@csulb.edu mfarquhar@ucsd.edu.

Insights

Cyclin-dependent kinase 5 (CDK5) phosphorylation of GIV-guanine exchange factor (GEF) activates Gαi and Gαs proteins, orchestrating cell migration over proliferation. This discovery clarifies the migration-proliferation dichotomy in cancer and development.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Biochemistry

Background:

  • Receptor tyrosine kinases (RTKs) signal through pathways that can promote cell migration or proliferation, but not simultaneously, a phenomenon known as the migration-proliferation dichotomy.
  • Epidermal growth factor (EGF) signaling favors cell migration over proliferation via noncanonical transactivation of Gαi proteins by the guanine exchange factor (GEF) GIV.
  • The upstream activators of GIV-GEF downstream of growth factor RTKs were previously unknown.

Purpose of the Study:

  • To elucidate the molecular mechanism by which GIV-GEF is activated by growth factor receptor signaling.
  • To identify the upstream kinase responsible for GIV-GEF activation.
  • To understand how this activation establishes the migration-proliferation dichotomy.

Main Methods:

  • Investigated the interaction between GIV and cyclin-dependent kinase 5 (CDK5).
  • Utilized phosphorylation site mapping to identify the key residue (Ser1674) on GIV.
  • Assessed the effects of GIV phosphorylation on Gαi and Gαs binding and activation.
  • Analyzed downstream signaling pathways, including Akt and MAPK.
  • Examined the impact on cell migration and proliferation in wound healing and cancer cell transmigration models.

Main Results:

  • CDK5 directly binds and phosphorylates GIV at Ser1674, near its GEF motif.
  • Phosphorylation of GIV at Ser1674 enables it to bind and activate Gαi, enhancing promigratory Akt signals.
  • Phosphorylated GIV also binds Gαs, promoting endosomal maturation and limiting mitogenic MAPK signals by reducing epidermal growth factor receptor (EGFR) transit time.
  • This phosphoevent directs cells towards migration during wound healing and cancer cell invasion.
  • Failure to phosphorylate Ser1674 prevents GIV binding to Gαi and Gαs, suppresses Akt signaling, enhances MAPK signaling due to delayed EGFR transit, and promotes proliferation.

Conclusions:

  • GIV-GEF activation is triggered by CDK5-mediated phosphorylation at Ser1674 in response to growth factors.
  • This phosphorylation event is a critical switch that orchestrates the migration-proliferation dichotomy.
  • The findings reveal a novel mechanism involving CDK5 and GIV in regulating cell movement and division, with implications for cancer invasion, wound healing, and development.

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

3.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K